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rug-Eluting Stent
ndothelium
resence or Dysfunction*
eleen M. M. van Beusekom, PHD,
atrick W. Serruys, MD, PHD
otterdam, the Netherlands
he Rosy Prophesy
rug-eluting stents (DES) have considerably improved the
reatment of coronary artery disease since their introduction in
001 due to the reduction of in-stent restenosis. It seemed for
while that the rosy prophecy made in 2000 was true.
See page 68
irst Cracks
n 2004, however, the first report on late stent thrombosis
LST) was published by McFadden et al. (1). More followed,
ncluding reports on delayed healing from autopsy (2) and
therectomy specimen (3). Meta-analyses now indicate that,
ndeed, this therapy is associated with an increased risk of late
tent thrombosis in someDES and applications. Daemen et al.
4) report an incidence of 0.6% per year, with a cumulative
ncidence of 2.4% at 4 years or higher in an all-comers
opulation. With 3 million stents being implanted worldwide
ach year, the risk of stent thrombosis is becoming a problem
f public health proportions.
elayed Endothelialization
inn et al. (5) from CVPath Institute Inc. point toward
elayed endothelialization as the main cause for late stent
hrombosis based on autopsy and pre-clinical studies using
enuded rabbit iliac arteries. This observation has not been
onsistently reproduced by other investigators or in other
odels (e.g., after direct stenting of swine coronary arteries)
6,7).
In this issue of JACC: Cardiovascular Interventions, Na-
azawa et al. (8) describe capture of CD34-positive cells via
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.h
From the Department of Cardiology, Erasmus Medical Center, Rotterdam, the
etherlands.enous stent (GS) technology (OrbusNeich Medical, Fort
auderdale, Florida) to enhance early endothelialization of
irolimus-eluting stents (SES) in swine coronary arteries.
canning electron microscopy was used to assess endothelial
resence and confocal microscopy to assess endothelial
unction and maturity (CD31 expression). Stent endotheli-
lization was studied in single and overlapping GS and SES
s well as in GS-modified SES.
They found that overlapping GS and SES increased the
ercentage stent strut endothelialization at 14 days as
ompared with SES alone (55% to 79%), but remained
ower than GS alone (99%). In other words, SES endothe-
ialization can indeed be enhanced by GS technology, but
his endothelium is still sensitive to sirolimus. Indeed,
verlapping SES and GS did not improve the number of
unctional endothelial cells at all as CD31 expression in
oth SES and GS–SES was the same: 40%. Interestingly,
verlapping 2 GS also decreased the number of functional
ndothelial cells (58% vs. 98%), despite the GS technology.
The direct modification of SES by the GS techno-
ogy did improve stent strut endothelialization and the
umber of functional endothelial cells. Each was improved
y 30% as compared with SES alone. These numbers,
owever, remained lower than in the GS alone group,
onfirming yet again the sensitivity of these cells for siroli-
us.
Nakazawa et al. (8) conclude that: “These studies dem-
nstrated that antibody-mediated endothelial progenitor
ell capture can enhance endothelial cell coverage and
aturation of endothelial cells on DES and may provide a
ew therapeutic approach.”
ndothelial Presence or
ndothelial Dysfunction?
hat can we learn from this study? The first phase of the
tudy shows that improving endothelial capture is not
ynonymous to improving endothelial function. It also
hows that overlapping a stent causes endothelial dys-
unction, even with GS. The second phase of the study
hows that in a less injurious setting, GS technology does
ncrease endothelialization in an SES environment and
mproves the number of functional endothelial cells in
erms of CD31 expression. However, the endothelial
ayer remains incomplete, and endothelial dysfunction is
till present. Whether GS technology is able to enhance
ate endothelialization at a time when the antibody
gainst CD34 is likely covered by a proteinaceous layer
9) is not known.
hronic Vascular Irritation
aking into account that not all DES that show delayed
ealing cause LST (2,3), and that LST occurs at a steady
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77ate long after the drugs have eluted from the stent, we have
o appreciate that there is more to LST than merely a partial
bsence of endothelial cells. Chronic vascular or endothelial
ysfunction, either stent-, drug-, or coating-induced, may
lay a more important role than is often suspected (10,11).
ndeed, the fact that DES are also associated with endo-
helial dysfunction of the coronary artery distal to the stent,
ven after all drug has been released (12–15), indicates the
hronic and extensive nature of this phenomenon.
mproving Endothelial Function
hile the GS technology enhances endothelialization of
ES, endothelial function remains impaired, and its long-
erm fate remains to be determined. We can expect that
mproving endothelialization will not be enough to prevent
ST as illustrated by the occurrence of LST even with GS
16). The future will lie in improving endothelial function.
owever, one can only improve that which is present. To
hat end, enhancing endothelialization by any means is an
mportant first step.
eprint requests and correspondence: Dr. Heleen van Beusekom,
horaxcenter, Room Ee2355a, Erasmus Medical Center, P.O. Box
040, 3000 CA Rotterdam, the Netherlands. E-mail: h.vanbeusekom@
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